brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
Published 6 months ago • 127 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
10:21
profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
0:39
stereotactic body rt in patients with oligometastatic crpc undergoing 1l treatment with abiraterone
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
1:19
highlights in prostate cancer from esmo
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer